Well, it was a very brief CC and the only real positive I could get from it was this statement from Jay.
<<<<The single ascending dose study is nearing completion consistent with our planned execution and timelines and the multiple ascending dose portion of the study is well on track for initiation shortly after completion of the SAD study.>>>>
Perhaps that is all we can expect for now. At least it hasn't been stopped for safety issues. That and they still have enough cash into Q4 2023.